Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
CureVac N.V is a biotechnology business based in the US. CureVac N-V shares (CVAC) are listed on the NASDAQ and all prices are listed in US Dollars. CureVac N-V employs 455 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $22.47 |
|---|---|
| 52-week range | $23.09 - $133.00 |
| 50-day moving average | $37.48 |
| 200-day moving average | $64.69 |
| Wall St. target price | $44.41 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.90 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.47 from 2022-01-19
| 1 week (2022-01-13) | -16.87% |
|---|---|
| 1 month (2021-12-20) | -42.09% |
| 3 months (2021-10-20) | -43.34% |
| 6 months (2021-07-20) | -57.31% |
| 1 year (2021-01-20) | -77.76% |
|---|---|
| 2 years (2020-01-16) | N/A |
| 3 years (2019-01-16) | N/A |
| 5 years (2017-01-16) | N/A |
| Revenue TTM | $67.8 million |
|---|---|
| Gross profit TTM | $34.7 million |
| Return on assets TTM | -24.68% |
| Return on equity TTM | -64.25% |
| Profit margin | 0% |
| Book value | $3.72 |
| Market capitalisation | $4.6 billion |
TTM: trailing 12 months
We're not expecting CureVac N-V to pay a dividend over the next 12 months.
CureVac N. V. , a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.